Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis
Identifieur interne : 000F27 ( Main/Exploration ); précédent : 000F26; suivant : 000F28Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis
Auteurs : L. Cummins [Australie] ; V. S. Katikireddi [Australie] ; S. Shankaranarayana [Australie] ; K. Y. C. Su [Australie] ; E. Duggan [Australie] ; V. Videm [Australie, Norvège] ; H. Pahau [Australie] ; R. Thomas [Australie]Source :
- Internal Medicine Journal [ 1444-0903 ] ; 2015-12.
Abstract
Background: While efficacy of combination treatment with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) (‘triple therapy’) has been shown in clinical trials, few studies have examined its longevity in a real‐life setting. Aim: Our aim was to assess the tolerability, longevity and efficacy of a triple disease‐modifying anti‐rheumatic drug (DMARD) regimen initiated in new‐onset rheumatoid arthritis (RA) patients. Methods: Patients who met 1987 American College of Rheumatology criteria for RA with disease duration less than 2 years were offered triple therapy upon diagnosis. Treatment was intensified according to a response‐driven step‐up algorithm, which included progression to leflunomide (LEF) or a biologic agent. Results: Of 181 new‐onset RA patients, 119 commenced triple therapy. Median duration of triple therapy was 39 weeks, and 23.5% remained on it at last follow up, with median follow up 104 weeks. Continuous therapy with any three‐DMARD combination (including LEF) occurred in 32% at last follow up, with median duration of 70 weeks. Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients. SSZ accounted for 49% of initial drug withdrawals for an adverse event. Continuation of three‐drug therapy did not significantly influence the proportion of patients achieving remission or low disease activity (LDA). Conclusions: Triple therapy in new‐onset RA was reasonably well tolerated, persisting for median 39 weeks. SSZ intolerance commonly reduces longevity of triple therapy. Treating to the target of remission or LDA is more important than the number of DMARD continued.
Url:
DOI: 10.1111/imj.12896
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000692
- to stream Istex, to step Curation: 000692
- to stream Istex, to step Checkpoint: 000072
- to stream Main, to step Merge: 000F28
- to stream Main, to step Curation: 000F27
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis</title><author><name sortKey="Cummins, L" sort="Cummins, L" uniqKey="Cummins L" first="L." last="Cummins">L. Cummins</name></author><author><name sortKey="Katikireddi, V S" sort="Katikireddi, V S" uniqKey="Katikireddi V" first="V. S." last="Katikireddi">V. S. Katikireddi</name></author><author><name sortKey="Shankaranarayana, S" sort="Shankaranarayana, S" uniqKey="Shankaranarayana S" first="S." last="Shankaranarayana">S. Shankaranarayana</name></author><author><name sortKey="Su, K Y C" sort="Su, K Y C" uniqKey="Su K" first="K. Y. C." last="Su">K. Y. C. Su</name></author><author><name sortKey="Duggan, E" sort="Duggan, E" uniqKey="Duggan E" first="E." last="Duggan">E. Duggan</name></author><author><name sortKey="Videm, V" sort="Videm, V" uniqKey="Videm V" first="V." last="Videm">V. Videm</name></author><author><name sortKey="Pahau, H" sort="Pahau, H" uniqKey="Pahau H" first="H." last="Pahau">H. Pahau</name></author><author><name sortKey="Thomas, R" sort="Thomas, R" uniqKey="Thomas R" first="R." last="Thomas">R. Thomas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:29DBE3741864C51565F2C98CC77215329978D3AE</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/imj.12896</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-BL4FV68G-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000692</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000692</idno><idno type="wicri:Area/Istex/Curation">000692</idno><idno type="wicri:Area/Istex/Checkpoint">000072</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000072</idno><idno type="wicri:doubleKey">1444-0903:2015:Cummins L:safety:and:retention</idno><idno type="wicri:Area/Main/Merge">000F28</idno><idno type="wicri:Area/Main/Curation">000F27</idno><idno type="wicri:Area/Main/Exploration">000F27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis</title><author><name sortKey="Cummins, L" sort="Cummins, L" uniqKey="Cummins L" first="L." last="Cummins">L. Cummins</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Katikireddi, V S" sort="Katikireddi, V S" uniqKey="Katikireddi V" first="V. S." last="Katikireddi">V. S. Katikireddi</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Shankaranarayana, S" sort="Shankaranarayana, S" uniqKey="Shankaranarayana S" first="S." last="Shankaranarayana">S. Shankaranarayana</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Su, K Y C" sort="Su, K Y C" uniqKey="Su K" first="K. Y. C." last="Su">K. Y. C. Su</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Duggan, E" sort="Duggan, E" uniqKey="Duggan E" first="E." last="Duggan">E. Duggan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Videm, V" sort="Videm, V" uniqKey="Videm V" first="V." last="Videm">V. Videm</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Immunology and Transfusion Medicine, St Olav University Hospital, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Pahau, H" sort="Pahau, H" uniqKey="Pahau H" first="H." last="Pahau">H. Pahau</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, R" sort="Thomas, R" uniqKey="Thomas R" first="R." last="Thomas">R. Thomas</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Australie</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="ISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1266">1266</biblScope><biblScope unit="page" to="1273">1273</biblScope><biblScope unit="page-count">9</biblScope><date type="published" when="2015-12">2015-12</date></imprint><idno type="ISSN">1444-0903</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1444-0903</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: While efficacy of combination treatment with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) (‘triple therapy’) has been shown in clinical trials, few studies have examined its longevity in a real‐life setting. Aim: Our aim was to assess the tolerability, longevity and efficacy of a triple disease‐modifying anti‐rheumatic drug (DMARD) regimen initiated in new‐onset rheumatoid arthritis (RA) patients. Methods: Patients who met 1987 American College of Rheumatology criteria for RA with disease duration less than 2 years were offered triple therapy upon diagnosis. Treatment was intensified according to a response‐driven step‐up algorithm, which included progression to leflunomide (LEF) or a biologic agent. Results: Of 181 new‐onset RA patients, 119 commenced triple therapy. Median duration of triple therapy was 39 weeks, and 23.5% remained on it at last follow up, with median follow up 104 weeks. Continuous therapy with any three‐DMARD combination (including LEF) occurred in 32% at last follow up, with median duration of 70 weeks. Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients. SSZ accounted for 49% of initial drug withdrawals for an adverse event. Continuation of three‐drug therapy did not significantly influence the proportion of patients achieving remission or low disease activity (LDA). Conclusions: Triple therapy in new‐onset RA was reasonably well tolerated, persisting for median 39 weeks. SSZ intolerance commonly reduces longevity of triple therapy. Treating to the target of remission or LDA is more important than the number of DMARD continued.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Norvège</li></country><region><li>Trøndelag</li></region><settlement><li>Trondheim</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Cummins, L" sort="Cummins, L" uniqKey="Cummins L" first="L." last="Cummins">L. Cummins</name></noRegion><name sortKey="Cummins, L" sort="Cummins, L" uniqKey="Cummins L" first="L." last="Cummins">L. Cummins</name><name sortKey="Duggan, E" sort="Duggan, E" uniqKey="Duggan E" first="E." last="Duggan">E. Duggan</name><name sortKey="Katikireddi, V S" sort="Katikireddi, V S" uniqKey="Katikireddi V" first="V. S." last="Katikireddi">V. S. Katikireddi</name><name sortKey="Pahau, H" sort="Pahau, H" uniqKey="Pahau H" first="H." last="Pahau">H. Pahau</name><name sortKey="Shankaranarayana, S" sort="Shankaranarayana, S" uniqKey="Shankaranarayana S" first="S." last="Shankaranarayana">S. Shankaranarayana</name><name sortKey="Su, K Y C" sort="Su, K Y C" uniqKey="Su K" first="K. Y. C." last="Su">K. Y. C. Su</name><name sortKey="Thomas, R" sort="Thomas, R" uniqKey="Thomas R" first="R." last="Thomas">R. Thomas</name><name sortKey="Thomas, R" sort="Thomas, R" uniqKey="Thomas R" first="R." last="Thomas">R. Thomas</name><name sortKey="Thomas, R" sort="Thomas, R" uniqKey="Thomas R" first="R." last="Thomas">R. Thomas</name><name sortKey="Videm, V" sort="Videm, V" uniqKey="Videm V" first="V." last="Videm">V. Videm</name></country><country name="Norvège"><region name="Trøndelag"><name sortKey="Videm, V" sort="Videm, V" uniqKey="Videm V" first="V." last="Videm">V. Videm</name></region><name sortKey="Videm, V" sort="Videm, V" uniqKey="Videm V" first="V." last="Videm">V. Videm</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:29DBE3741864C51565F2C98CC77215329978D3AE
|texte= Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |